Stemrim Secures Mexican Patent for Cartilage Disease Treatment Using Ledasumtid

TOKYO, Jul 22 (Pulse News Wire) – StemRIM Inc. (4599.T) announced that a patent application related to the therapeutic use of Ledasumtid (HMGB1 fragment peptide) for cartilage diseases such as traumatic chondral defects, osteoarthritis, and osteochondritis dissecans was registered in Mexico.

The development candidate originated from StemRIM's regenerative medicine technology licensed to Shionogi & Co., Ltd. This patent, filed under number MX/a/2021/4,758, covers the creation of treatment options based on Ledasumtid for various cartilage conditions. It expands the potential applications of Ledasumtid, which mobilizes mesenchymal stem cells (MSCs) via intravenous administration to promote tissue repair and regeneration in damaged areas. Soft tissue injuries often lead to chronic pain and joint dysfunction due to limited self-repair capabilities.

Ledasumtid’s non-invasive delivery method through IV injection makes it a promising option for future medical treatments. However, there will be no impact on the fiscal year ending July 2026 performance figures. Any significant developments will be disclosed promptly. The patent filing underscores StemRIM's commitment to advancing regenerative therapies and expanding the utility of Ledasumtid across multiple clinical indications.